OptimizeRx reported a 20% revenue decline and a $(3) net loss for the nine months ended September 30, 2026, versus $112 net income in 2025. Disclosure controls also remained ineffective due to a material weakness.
OPRX · OptimizeRx Corp
5 customers — 47% of revenue (the years ended December 31, 2025)
“Although we have over 100 pharmaceutical manufacturers as customers, our top five customers represented approximately 47% and 49% of our revenue for the years ended December 31, 2025 and 2024, respectively.”
One customer — 10% of revenue (fiscal 2025)
“As discussed under “Net Revenues” below, one customer that accounted for approximately 10% of our total revenue in fiscal 2025 did not generate revenue during the current period and, although we have recently contracted with this customer and expect to recognize revenue under this contract in the current year, we do not expect this customer to return to its fiscal 2025 level in the current year and future revenue from this customer is uncertain.”
3 customers — 10% of revenue (2025)
“Three customers in 2025 and two customers in 2024 each represented more than 10% of our revenues.”
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 54%
- Last earnings
- Nov 11, 2026
- Latest filing
- 10-Q · Nov 13
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
OptimizeRx reported Q3 2026 revenue of $21.6 million, down 17%, and adjusted EBITDA of $6.3 million; it updated 2026 revenue guidance to $87-$93 million while keeping adjusted EBITDA guidance at $21-$25 million.
OptimizeRx reported third quarter revenue of $21.6 million and adjusted EBITDA of $6.3 million, both exceeding consensus expectations, and updated full-year 2026 revenue guidance to $87 million to $93 million while maintaining adjusted EBITDA guidance of $21 to $25 million.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 11, 2026TL;DR. OptimizeRx delivered a consensus revenue and adjusted EBITDA beat, expanded profitability by more than 900 basis points, and saw encouraging 2027 RFP momentum, a returning major customer, new programmatic distribution, and lower debt. However, revenue declined 17%, 2026 contracted revenue remained approximately 20% below the prior year, full-year revenue guidance was reduced to $87 million-$93 million, and fourth-quarter execution risk increased.
- + Q3 revenue of $21.6 million and adjusted EBITDA of $6.3 million both exceeded consensus expectations.
- + Adjusted EBITDA increased approximately 23%, while adjusted EBITDA margin expanded more than 900 basis points. new
- + Contracted revenue for the 2027 RFP season was running close to 20% ahead year over year. new
- + A previously displaced top-five client returned and began reinvesting in new solutions with OptimizeRx. new
- + The PulsePoint integration is expected to contribute approximately 250,000 incremental NPIs to PulsePoint's network. new
- + Debt principal repayments since June 30, 2026 reduced outstanding principal to $10.4 million. new
- − Q3 revenue decreased 17% to $21.6 million from $26.1 million in Q3 2025. new
- − Full-year 2026 revenue guidance was updated to $87 million-$93 million. new
- − Contracted revenue for 2026 continued to track approximately 20% below the comparable prior-year level. new
- − Net revenue retention fell to 83% from 121% in the prior-year period.
- − Management cited reduced large-customer spending, budget pressure, and spending delays associated with MFN pricing uncertainty. new
- − Limited visibility into fourth-quarter buy-up activity increased execution risk and reduced the odds of a near-term revenue upside surprise. new
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $14.55M | For the Nine Months Ended September 30, 2026 | — |
|
|
|||
| Adjusted EBITDA margin non-GAAP | 29% | third quarter of 2026 | — |
| Average revenue per top 20 pharmaceutical manufacturer | 2.5M | Rolling Twelve Months Ended September 30, 2026 | — |
| contracted revenue | 90% | full year 2026 | — |
| EBITDA margin | 29% | this quarter | — |
| EHR and e-prescribing systems | 400 | September | — |
| Net revenue retention | 83% | Rolling Twelve Months Ended September 30, 2026 | — |
| Non-GAAP net income non-GAAP | $8.79M | For the Nine Months Ended September 30, 2026 | — |
|
|
|||
| Non-GAAP net income per share - Diluted non-GAAP | $0.46 | For the Nine Months Ended September 30, 2026 | — |
|
|
|||
| Percent of total revenue attributable to top 20 pharmaceutical manufacturers | 53% | Rolling Twelve Months Ended September 30, 2026 | — |
| Revenue per average full-time employee | 706K | Rolling Twelve Months Ended September 30, 2026 | — |
| verified healthcare professionals | 800,000 | September | — |
| Average revenue per top 20 pharmaceutical manufacturers | 2.66M | Rolling Twelve Months Ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Health Information Services — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
OPRX
this stock
OptimizeRx Corp
|
$126.68M | -45.4% | +18.8% | 25.8 | 6.3% |
|
VEEV
Veeva Systems Inc
|
$43.10B | +19.3% | +28.1% | 43.6 | 2.4% |
|
PMDIY
Pro Medicus Ltd.
|
$14.81B | -14.6% | — | — | 0.0% |
|
BTSG
BrightSpring Health Services, Inc.
|
$12.50B | +67.8% | +28.2% | 34.2 | 5.8% |
|
TEM
Tempus AI, Inc.
|
$9.86B | -8.5% | +83.4% | — | 13.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 13, 2026
- This year
- 16
OptimizeRx reported a 20% revenue decline and a $(3) net loss for the nine months ended September 30, 2026, versus $112 net income in 2025. Disclosure controls also remained ineffective due to a material weakness.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| OPRX | -8.7% | -26.8% | +26.9% | -28.1% | -45.4% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | -0.2% | -17.6% | +36.1% | -19.4% | -46.5% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.